Tamoxifen activates cellular phospholipase C and D and elicits protein kinase C translocation

International Journal of Cancer

Volumn 70, Issue 5, 1997, Pages 567-574

  Cabot, Myles C ^a,d   Zhang, Zu Chuan ^a,b   Cao, Hui Ting ^a,b   Lavie, Yaakov ^a   Giuliano, Armando E ^a   Han, Tie Van ^a   Jones, Ralph C ^a,c  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d SAINT JOHN'S HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ALCOHOL; CHOLINE; DIACYLGLYCEROL; ETHANOLAMINE; PHORBOL ESTER; PHOSPHOLIPASE C; PHOSPHORYLCHOLINE; PROTEIN KINASE C; TAMOXIFEN;

ARTICLE; BREAST CELL; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS, HORMONAL; DIGLYCERIDES; DOWN-REGULATION; ENZYME ACTIVATION; HUMANS; HYDROLYSIS; PHOSPHATIDIC ACIDS; PHOSPHATIDYLCHOLINES; PHOSPHOLIPASE C; PHOSPHOLIPASE D; PROTEIN KINASE C; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 0030935449     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970304)70:5<567::AID-IJC13>3.0.CO;2-A     Document Type: Article

References (28)

1. ANDERSSON, M., STORM, H.H. and MOURIDSEN, H.T., Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol., 31, 259-263 (1992).
2. ASAOKA, Y., NAKAMURA, S.I., YOSHIDA, K. and NISHIZUKA, Y., Protein kinase C. calcium and phospholipid degradation. Trends biochem. Sci., 17, 414-418 (1992).
3. BIGNON, E., PONS, M., DORÉ, J.C., GILBERT, J., OJASOO, T., MIQUEL, J.F., RAYNAUD, J.P. and DE PAULET, A.C., Influence of di- and tri-phenylethylene estrogen/antiestrogen structure on the mechanisms of protein kinase C inhibition and activation as revealed by a multivariate analysis. Biochem. Pharmacol., 42, 1373-1383 (1991).
4. BLIGH, E.G. and DYER, W.T., A rapid method of total lipid extraction and purification. Canad. J. biochem. Physiol., 37, 911-917 (1959).
5. BRANDES, L.J., BOGDANOVIC, R.P., CAWKER, M.D. and LABELLA, F.S., Histamine and growth: interaction of antiestrogen binding site ligands with a novel histamine site that may be associated with calcium channels. Cancer Res., 47, 4025-4031 (1987).
6. BUTIA, A., MACLENNAN, K., FLANDERS, K.C., SACKS, N.P.M., SMITH, I., McKINNA, A., DOWSETT, M., WAKEFIELD, L.M., SPORN, M.B., BAUM, M. and COLLETTA, A.A., Induction of transforming growth factor βl in human breast cancer in vivo following tamoxifen treatment. Cancer Res., 52, 4261-4264 (1992).
7. CABOT, M.C., GIULIANO, A.E., VOLNER, A. and HAN, T.-Y., Tamoxifen retards glycosphingolipid metabolism in human cancer cells. FEBS Lett., 392, 129-131 (1996).
8. CABOT, M.C., WELSH, C.J., ZHANG, Z. and CAO, H., Evidence for a protein kinase C-directed mechanism in the phorbol diester-indueed phospholipase D pathway of diacylglycerol generation from phosphatidylcholine. FEBS Lett., 245, 85-90 (1989).
9. CABOT, M.C., ZHANG, Z.-C. and GIULIANO, A.E., Tamoxifen elicits rapid transmembrane lipid signal responses in human breast cancer cells. Breast Cancer Res. Treat.. 36, 299-306 (1995).
10. COULDWELL, W.T., WEISS, M.H., DEGIORGIO, C.M., WEINER, L.P., HINTON, D.R., EHRESMANN, G.R., CONTI, P.S. and APUZZO, M.L., Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery, 32, 485-489 (1993).
11. DEL PRETE, S.A., MAURER, L.H., O'DONNELL, J., FORCIER, R. and LEMARBRE, P., Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat. Rep., 68, 1403-1405 (1984).
12. GROSS, C., Yu, M., VAN HERLE, A.J., GIULIANO, A.E. and JUILLARD, G.J.F., Presence of a specific antiestrogen binding site on human follicular thyroid carcinoma cell line (UCLA RO 82 W-I): inhibition by an endogenous ligand present in human serum. J. Clin. Endocrinol. Metabol., 77, 1361- 1366 (1993).
13. HA, K. and EXTON, J.H., Differential translocation of protein kinase C isozymes by thrombin and platelet-derived growth factor. J. biol. Chem., 268, 10534-10539 (1993).
14. HARDCASTLE, I.R., ROWLANDS, M.G., HOUGHTON, J., PARR, I.B., POTTER, G.A. and JARMAN, M., Rationally designed analogues of tamoxifen with improved calmodulin antagonism. J. med. Chem., 38, 241-248 (1995).
15. HUANG, C. and CABOT, M.C., Vasopressin-induced polyphosphoinositide and phosphatidylcholine degradation in fibroblasts: temporal relationship for formation of phospholipase C and phospholipase D hydrolysis products. J. biol. Chem., 265, 17468-17473 (1990).
16. ISSANDOU, M., FAUCHER, C., BAYARD, F. and DARBON, J.M., Opposite effects of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells. Cancer Res., 50, 5845-5850 (1990).
17. JOHNSON, S.R.D., HAYNES, B.P., SACKS, N.P.M., MCKINNA, J.A., GRIGGS, L.J., JARMAN, M., BAUM, M., SMITH, I.E. and DOWSETT, M., Effect of estrogen receptor status and time on the intra-tumoral accumulation of tamoxifen and N-desmethyltamoxifen following short term therapy in human primary breast cancer. Breast Cancer Res. Treat., 28, 241-250 (1993).
18. KELLEN, J.A. (ed.), Tamoxifen: beyond the antiestrogen. Birkhäuser. Boston (1996).
19. Kiss, Z., Tamoxifen stimulates phospholipase D activity by an estrogen receptor-independent mechanism. FEBS Lett., 355, 173-177 (1994).
20. Kiss, Z. and GARAMSZEGI, N., Overexpression of protein kinase C-ε enhances the stimulatory effect of ethanol on phospholipase C-mediated hydrolysis of phosphatidylethanolamine in NIH 3T3 ribroblasts. FEBS Lett., 333, 229-232 (1993).
21. LAVIE, Y., JONES, R.C., CAO, H.T., JARMAN, M., HARDCASTLE, T.R., GIULLIANO, A.E. and CABOT, M.C., Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 cells. Proc. Amer. Assoc. Can. Res., 37, 423 (1996).
22. LERNER, L.J. and JORDAN, V.C., Development antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res., 50, 4177-4189 (1990).
23. LIEN, E.A., SOLHEIM, E. and UELAND, P.M., Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res., 51, 4837-1844 (1991).
24. NISHIZUKA, Y., Protein kinase C and lipid signaling for sustained cellular responses. FASEB J., 9, 484-496 (1995).
25. O'BRiAN, C.A., LISKAMP, R.M., SOLOMON, D.H. and WEINSTEIN, I.B., Inhibition of protein kinase C by tamoxifen. Cancer Res., 45, 2462-2465 (1985).
26. PFEILSCHIFTER, J. and MERRIWEATHER, C., Extracellular ATP and UTP activation of phospholipase D is mediated by protein kinase C-ε in rat renal mesangial cells. Brit. J. Pharmacol., 110, 847-853 (1993).
27. RAMU, A., RAMU, N. and ROSARIO, L., Circumvention of multidrug- resistance in P388 cells is associated with a rise in the cellular content of phosphatidylcholine. Biochem. Pharmacol., 41, 1455-1461 (1991).
28. SMITH, D.C. and TRUMP, D.L., A phase I trial of high-dose oral tamoxifen and CHOPE. Cancer Chemother. Pharmacol., 36, 65-68 (1995).